KZR's logo.
Ticker Symbol: KZR

Kezar Life Sciences Inc

$11.59 - 20-11-2024 4 p.m. ET

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001645666

Company Profile

kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology
Standard Industrial Classification Code (SIC code): 2834
Address: 4000 Shoreline Ct Ste 300
CEO: John Fowler
Tags:
  • Health Technology
  • Biotechnology

Pricing

Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $1.04
Change: -$0.11 ( -9.56%)
Days Range: $1.03 - $1.13
Beta: 1.51
52wk. High: $8.25
52wk. Low: $0.86
Ytd. Change -93.23%
50 Day Moving Average: $1.13
200 Day Moving Average: $2.06
Shares Outstanding: 72692963

Valuation

Market Cap: 7.6B
PE Ratio: -
EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A